EpiVax is truly proud to be one of the founding sponsors of the “Vaccine Renaissance”, an annual event held in our hometown. Many of the nation’s top brass in the vaccine research and development field will be in Providence over the next three days for the 4th Annual Vaccine Renaissance Conference.
Beginning Thursday, leaders in the field will meet at the University of Rhode Island’s Feinstein campus to discuss the latest trends in vaccine research, vaccine delivery, clinical trials and basic immunology. The conference will continue on Friday and Saturday at the Hotel Providence located at 139 Mathewson Street. The conference is free and open to the public.
This year’s conference will provide a great opportunity to learn about vaccines from the top researchers in the world. Among guest speakers scheduled to speak are Dr. Niranjan Sardesai of Inovio Pharmaceuticals. Dr. Sardesai will present a clinical trial update on the therapeutic HPV vaccine. Also on the agenda is Dr. Vincent Tuohy of the Lerner College of Medicine at the Cleveland Clinic. Dr. Tuohy will highlight his findings on a prophylactic breast cancer vaccination. Dr. Katharine Kripke of the National Institutes of Health will provide an update on the current status of HIV vaccine research.
Joining Dr. Kripke from the NIH will be renowned immunologist Dr. Polly Matzinger. Dr. Matzinger’s presentation will focus on balancing tolerance and intolerance in vaccine design. A reception and award ceremony named in Dr. Matzinger’s honor will follow her presentation on Friday.
The conference comes as I’Cubed continues its growth as a major research institute. I’Cubed is headed by EpiVax CEO Annie De Groot, Principal Investigator of the $13 million National Institutes of Health-funded Translational Immunology Research and Accelerated Vaccine Development (TRIAD) program and her close collaborator, Co-Director Denice Spero, a highly experienced drug developer. The TRIAD grant helped launch I’Cubed at URI’s Providence Biotechnology Center. TRIAD also established De Groot’s in silico (via computer simulation), in vitro and in vivo vaccine research program at the University’s Providence campus.
More than $14M has been dedicated to fuel applications of the gene-to-vaccine approach originally pioneered by EpiVax, an approach now adopted by the I’Cubed for non-commercial vaccine development programs.
For more information regarding the 4th Annual Vaccine Renaissance Conference or I’Cubed, please visit http://www.Immunome.org.